Fasting and postprandial levels of a novel anorexigenic peptide nesfatin in childhood obesity.
BACKGROUND
Nesfatin-1, a recently discovered anorexigenic peptide, is expressed in several tissues, including pancreatic islet cells and central nervous system. However, its pathophysiological role in the development of obesity and insulin resistance remains unknown.


OBJECTIVE
To investigate the possible involvement of nesfatin-1 in the pathogenesis of childhood obesity, we examined the relationship between fasting and postprandial nesfatin-1 concentrations and metabolic/antropometric parameters in obese children.


METHODS
The study included obese children with a body mass index >95th percentile. Fasting serum glucose, insulin, lipid profile, fasting and postprandial (120th min) nesfatin-1 levels were measured to evaluate the metabolic parameters. Different cutoff values for prepubertal and pubertal stages were used to determine the status of insulin resistance (HOMA-IR) (prepubertal >2.5, pubertal >4). The percentage of body fat was measured using bioelectric impedance analysis.


RESULTS
Seventy-one obese children were included in this study. There was no statistically significant difference between fasting and postprandial nesfatin-1 levels in obese subjects (0.70 ± 0.15 and 0.69 ± 0.14 ng/mL, p>0.05, respectively). Insulin resistance was observed in 58% (41/71) of the cases. There was no significant difference in either fasting or postprandial serum nesfatin-1 levels between the insulin-resistant and non-resistant groups (p>0.05). There was no correlation between fasting and postprandial serum nesfatin-1 levels and anthropometric and metabolic parameters in insulin-resistant and non-resistant groups.


CONCLUSIONS
In this study, there was no significant increase in the postprandial level of nesfatin-1. This observation suggested that oral glucose load in obese children may not be sufficient for nesfatin-1 response and that nesfatin-1 may not have an effect as a short-term regulator of food intake.
Ahmet
A
Anık
Gönül
G
Çatlı
Ayhan
A
Abacı
Tuncay
T
Küme
Ece
E
Bober
D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000097:blood*; D002648:Child; D004268:DNA-Binding Proteins / Q000097:blood*; D005215:Fasting / Q000097:blood*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D009419:Nerve Tissue Proteins / Q000097:blood*; D000080866:Nucleobindins; D063766:Pediatric Obesity / Q000097:blood*; D019518:Postprandial Period
D001786:Blood Glucose; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; D007328:Insulin; D008055:Lipids; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins